NCT01559103View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

MEDI5117

Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg

BIOLOGICAL

MEDI5117 Placebo

Intravenous infusion administered over 60 minutes

Trial Locations (3)

Unknown

Novo Nordisk Investigational Site, Overland Park

Novo Nordisk Investigational Site, Berlin

Novo Nordisk Investigational Site, Belfast

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY